GlassScriptPhysician profile
Sarah Sharkey
NPI 1184078719
$3,680.98
in general payments reported to CMS, 2019-2025
29 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2021: $457 · 2022: $523 · 2023: $711 · 2024: $714 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $689.65 | 2022-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $602.89 | 2024-2025 | |
| Glaxosmithkline, LLC. | $397.68 | 2021-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $364.83 | 2021-2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.81 | 2021-2024 | Ofev |
| Insmed, INC. | $174.88 | 2021-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $168.88 | 2021-2024 | Xarelto |
| Abiomed | $134.90 | 2024 | Impella |
| United Therapeutics Corporation | $124.47 | 2021 | |
| Merck Sharp & Dohme LLC | $112.89 | 2021-2025 | Winrevair, Dificid, Zerbaxa |
| Edwards Lifesciences Corporation | $107.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.52 | 2023-2024 | Glassia |
| Vertex Pharmaceuticals Incorporated | $49.79 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $47.28 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $37.82 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.52 | 2024 | Yupelri |
| Grifols USA, LLC | $32.45 | 2021-2025 | Prolastin-C Liquid |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Genentech USA, INC. | $26.22 | 2022 | |
| Tactile Systems Technology INC | $21.02 | 2024 | Entre Plus, Flexitouch Plus |
| Verona Pharma, INC. | $19.98 | 2025 | Ohtuvayre |
| Alexion Pharmaceuticals, INC. | $18.90 | 2023 | Soliris |
| Amgen INC. | $16.95 | 2025 | Tezspire |
| Viatris Specialty LLC | $16.15 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $15.02 | 2025 | Acthar |
| Gilead Sciences, INC. | $14.86 | 2021 | |
| Baxter Healthcare | $13.88 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Medtronic, INC. | $13.67 | 2025 | Illumisite |
| Pfizer INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Sharkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.